The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial
Official Title: A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY Trial
Study ID: NCT03753919
Brief Summary: This is a prospective, multi-centre, open label, stratified, exploratory phase II study evaluating the efficacy and safety of durvalumab plus tremelimumab in different cohorts of patients with thyroid cancers.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Instituto Catalán de Oncología de Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain
Hospital Provincial de Castellón, Castelló, Valencia, Spain
Hospital Clínic Barcelona, Barcelona, , Spain
Hospital Universitari Vall d'Hebron, Barcelona, , Spain
MD Anderson Cancer Center, Madrid, , Spain
Hospital Clínico San Carlos, Madrid, , Spain
Hospital Universitario 12 de Octubre, Madrid, , Spain
Hospital Universitario HM Sanchinarro, Madrid, , Spain
Hospital Universitario La Paz, Madrid, , Spain
Hospital Universitario Ramón y Cajal, Madrid, , Spain
Hospital General Universitario Morales Meseguer, Murcia, , Spain
Hospital Universitario Virgen de la Victoria, Málaga, , Spain
Clínica Universidad de Navarra, Pamplona, , Spain
Instituto Valenciano de Oncología, Valencia, , Spain
Complejo Hospitalario Universitario de Vigo (CHUVI), Vigo, , Spain
Name: Jaume Capdevila, M.D., Ph.D.
Affiliation: Hospital Universitari Vall d'Hebron, Barcelona
Role: STUDY_CHAIR